Ascendis Pharma Endocrinology Division A/S: Financial statements 2017
CVR: 32323537
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
Ascendis Pharma Endocrinology Division A/S (CVR 32323537) has filed annual accounts for 2017. In 2017, the company reported a gross profit of EUR -57,341,190 and a net result of EUR -60,324,124 compared with EUR -44,006,494 the year before. Equity in the 2017 report amounted to EUR -148,586,613.
- Gross Profit
- EUR -57,341,190
- Profit/Loss
- EUR -60,324,124
- Equity
- EUR -148,586,613
- Total Assets
- EUR 12,458,025
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2017 | - | -57.3M EUR | -60.3M EUR | -148.6M EUR | 0 |
| 2016 | - | -42.3M EUR | -44M EUR | -88.3M EUR | - |
| 2015 | - | -28.8M EUR | -29.6M EUR | -44.3M EUR | - |
| 2014 | - | -11.2M EUR | -11.5M EUR | -14.7M EUR | - |
| 2013 | - | -46.2M | -47.3M | -36.9M | - |
Official annual report
Keep an eye on Ascendis Pharma Endocrinology Division A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
Ascendis Pharma Endocrinology Division A/S has published its annual report for 2016. Gross profit came to DKK -42,307,040, and the net result was DKK -44,006,494.
About Ascendis Pharma Endocrinology Division A/S
Ascendis Pharma Endocrinology Division A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA, GROWTH DISORDERS DIVISION A/S and ACP 30.06.2012 2 A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported revenue of EUR 140,817,000 and a net result of EUR -38,806,000 compared with EUR -121,118,000 the year before. Equity in the 2025 report amounted to EUR -935,650,000.
